Toxicogenetics of antiretroviral treatment (II): Neurotoxicity, hepatotoxicity, lactic acidosis, kidney damage, and other adverse effects of antiretroviral drugs;Toxicogenética del tratamiento antirretroviral (y II): Neurotoxicidad, hepatotoxicidad, acidosis láctica, daño renal y otros efectos adversos del tratamiento antirretroviral

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 26, Issue SUPPL. 6, 2008, Pages 24-33

  Hellín, Victoria Sánchez ^a   Gutiérrez Rodero, Félix ^a,b  

^a HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^b MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

Author keywords

Adverse effects; AIDS; Antiretroviral treatment; HIV; Pharmacogenetics; Toxicity

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; BREAST CANCER RESISTANCE PROTEIN; CYTOCHROME P450 2B6; DIDANOSINE; DNA DIRECTED DNA POLYMERASE GAMMA; EFAVIRENZ; EMTRICITABINE; GLUCURONOSYLTRANSFERASE 1A1; GLYCOPROTEIN P; HEMOJUVELIN; HLA C ANTIGEN; HLA CW8 ANTIGEN; HLA DR ANTIGEN; INDINAVIR; LAMIVUDINE; MULTIDRUG RESISTANCE PROTEIN 1; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; PROTEIN; SPINK 1 PROTEIN; STAVUDINE; TENOFOVIR; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG; ZIDOVUDINE;

ADVERSE OUTCOME; ALLELE; ANTIVIRAL THERAPY; CAUCASIAN; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CODON; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG WITHDRAWAL; FEVER; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC RISK; GENOTYPE; HAPLOTYPE; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; JAPAN; KIDNEY INJURY; KIDNEY TUBULE DISORDER; LACTIC ACIDOSIS; LIVER TOXICITY; MAJOR HISTOCOMPATIBILITY COMPLEX; MITOCHONDRIAL GENOME; NEPHROTOXICITY; NEUROTOXICITY; PANCREATITIS; PERIPHERAL NEUROPATHY; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TOXICOGENETICS;

EID: 75449103597     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/S0213-005X(08)76509-1     Document Type: Article

References (78)

1. A. Telenti, and U.M. Zanger Pharmacogenetics of anti-HIV Drugs Annu Rev Pharmacol Toxicol 48 2008 9.1 9.30
2. M.T. Huisman, J.W. Smit, and A.H. Schinkel Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors AIDS 14 2000 237 242 (Pubitemid 30132917)
3. J.D. Schuetz, M.C. Connelly, D. Sun, S.G. Paibir, P.M. Flynn, and R.V. Srinivas MRP4: A previously unidentified factor in resistance to nucleoside-based antiretroviral drugs Nat Med 5 1999 1048 1051 (Pubitemid 29439577)
4. J. Wijnholds, C.A. Mol, L. Van Deemter, M. De Haas, G.L. Scheffer, and F. Baas Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleoside analogs Proc Natl Acad Sci USA 97 2000 7476 7481 (Pubitemid 30431488)
5. H. Izzedine, V. Launaty-Vacher, and G. Deray Renal tubular transporter and antiretroviral drugs: an update AIDS 19 2005 455 462 (Pubitemid 40515848)
6. S. Staszewski, J. Morales-Ramírez, K. Tashima, A. Rachlis, D. Skiest, and J. Stanford Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults N Engl J Med 341 1999 1865 1873
7. C. Marzolini, A. Telenti, L. Decosterd, J. Biollaz, and T. Buclin Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients AIDS 15 2001 1193 1194 (Pubitemid 32549879)
8. F. Gutiérrez, A. Navarro, S. Padilla, R. Antón, M. Masiá, and J. Borrás Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring Clin Infect Dis 41 2005 1648 1653 (Pubitemid 41691605)
9. C. Csajka, C. Marzolini, K. Fattinger, L.A. Décosterd, J. Fellay, and A. Telenti Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection Clin Pharmacol Ther 73 2003 20 30 (Pubitemid 36158483)
10. B. Hasse, H. Gunthard, G. Bleiber, and M. Krause Efavirenz intoxication due to slow hepatic metabolism Clin Infect Dis 40 2005 e22 e23
11. E. Lowenhaupt, K. Matson, B. Qureishi, A. Saitoh, and D. Pugatch Psycosis in a 12-year-old HIV-positive girl with an increased serum concentration of efavirenz Clin Infect Dis 45 2007 e128-e30
12. L. Stahle, L. Moberg, J.O. Svensson, and A. Sonnerborg Efavirenz plasma concentrations in HIV-infected patients:inter-and intraindividual variability and clinical effects Ther Drug Monit 26 2004 267 270 (Pubitemid 38703012)
13. B.A. Ward, J.C. Gorski, D.R. Jones, S.D. Hall, D.A. Flockhart, and Z. Desta Thecytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primaryand secondary metabolism: implication for HIV/AIDS therapy and utility ofefavirenz as a substrate marker of CYP2B6 catalytic activity J Pharmacol Exp Ther 306 2003 287 300 (Pubitemid 36734384)
14. K. Klein, T. Lang, T. Saussele, E. Barbosa-Sicard, and W.H. Schunck Genetic variability of CYP2B6 in populations of African and Asian origin: allelefrequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz Pharmacogenet. Genomics 15 2005 861 873 (Pubitemid 41666768)
15. T. Lang, K. Klein, J. Fischer, A.K. Nüssler, P. Neuhaus, and U. Hofmann Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver Pharmacogenetics 11 2001 399 415 (Pubitemid 32656581)
16. D.W. Haas, H. Ribaudo, R. Kim, C. Tierney, G. Wilkinson, and R. Gulick Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Group study AIDS 18 2004 2391 2400 (Pubitemid 40065906)
17. K. Tsuchiya, H. Gatanaga, N. Tachikawa, K. Teruya, Y. Kikuchi, and M. Yoshino Homozygous CYP2B6*6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens Biochem Biophys Res Comm 319 2004 1322 1326 (Pubitemid 38759555)
18. S. Rodriguez-Novoa, P. Barreiro, A. Rendón, I. Jiménez-Nacher, J. Gonzalez-Lahoz, and V. Soriano Influence of 516 G>T polymorphisms at the gen encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects Clin Infect Dis 40 2005 1358 1361 (Pubitemid 40570249)
19. M. Rotger, S. Colombo, H. Furrer, G. Bleiber, T. Buclin, and B.L. Lee Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapina in HIV-infected patients Pharmacogenet Genomics 15 2005 1 5 (Pubitemid 43205520)
20. D.W. Haas, L.M. Smeaton, R.W. Shafer, G.K. Robbins, and G.D. Morse Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfinavir: an Adult Aids Clinical Trials Group Study J Infect Dis 192 2005 1931 1942
21. H.J. Ribaudo, D.W. Haas, C. Tierney, R.B. Kim, and G.R. Wilkinson Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group study Clin Infect Dis 42 2006 401 407 (Pubitemid 43122320)
22. J. Wang, A. Sonnerborg, A. Rane, F. Josephson, S. Lundgren, and L. Stahle Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz Pharmacogenet Genomics 16 2006 191 198 (Pubitemid 43312581)
23. M. Rotger, H. Tegude, S. Colombo, M. Cavassini, H. Furrer, and L. Dacosterd Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals Clin Pharmacol Ther 81 2007 557 566 (Pubitemid 46454205)
24. J. Fellay, C. Marzolini, E.R. Meaden, D.J. Back, T. Buclin, and J.P. Chave Response to antiretroviral treatment in HIV-infected individuals with allelic variants of the multidrug resistant transporter 1: a pharmacogenetics study Lancet 359 2002 30 36 (Pubitemid 34119193)
25. A.A. Motsinger, M.D. Ritchie, R.W. Shafer, G.K. Robbins, G.D. Morse, and L. Labbe Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study Pharmacogenet Genomics 16 2006 837 845 (Pubitemid 44632298)
26. H. Gatanaga, T. Hayashida, K. Tsuchiya, M. Yoshino, T. Kuwahara, and H. Tsukada Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6*6 and*26 Clin Infect Dis 45 2007 1230 1237 (Pubitemid 47580326)
27. D.T. Dieterich, P.A. Robinson, J. Love, and J.O. Stern Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors Clin Infect Dis 38 Suppl 2 2004 S80 S89
28. J.O. Stern, P.A. Robinson, J. Love, S. Lanes, M.S. Imperiale, and D.L. Mayers A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients J Acquir Immune Defic Syndr 34 Suppl 1 2003 S21 S33
29. S.M. Patel, S. Johnson, S.M. Belknap, J. Chan, B.E. Sha, and C. Bennett Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV infected individuals J Acquir Immune Defic Syndr 35 2004 120 125 (Pubitemid 38133733)
30. M. Martin, D. Nolan, I. James, P. Cameron, J. Keller, and C. Moore Predisposition to nevirapine hypersensitivity associated with HLA-DBR1*0101 and abrogated by low CD4 T-cell counts AIDS 5 2005 97 99 (Pubitemid 40111026)
31. R. Littera, C. Carcassi, A. Masala, P. Piano, P. Serra, and F. Ortu HLA-dependent hypersensitivity to nevirapina in Sardinian HIV patients AIDS 20 2006 1621 1626 (Pubitemid 44162404)
32. H. Gatanaga, H. Yazaki, J. Tanuma, M. Honda, I. Genka, and K. Teruya HLA-Cw8 primarily associated with hypersensitivity to nevirapine AIDS 21 2007 264 265 (Pubitemid 46036947)
33. E. Stormer, L.L. von Moltke, M.D. Perloff, and D.J. Greenblatt Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture Pharm Res 19 2002 1038 1045 (Pubitemid 34804248)
34. L.M. Almond, D. Edirisinghe, M. Dalton, A. Bonington, D.J. Back, and S.H. Khoo Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals Clin Pharmacol Ther 78 2005 132 142 (Pubitemid 41112281)
35. M. Ritchie, D.W. Haas, A. Motsinger, J. Donahue, H. Erdem, and S. Raffanti Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse transcriptase inhibitor hepatotoxicity Clin Infect Dis 43 2006 779 782 (Pubitemid 44330745)
36. D.W. Haas, J. Barlett, J. Andersen, I. Sanne, G. Wilkinson, and J. Hinkle Pharmacogenetics of nevirapine associated hepatotoxicity: an adult AIDS Clincal Trials Group collaboration Clin Infect Dis 43 2006 783 786 (Pubitemid 44330746)
37. G.L. Plosker, and S. Noble Indinavir: a review of its use in the management of HIV infection Drugs 58 1999 1165 1203 (Pubitemid 30055050)
38. A.J. Busti, R.G. Hall, and D.M. Margolis Atazanavir for the treatment of human immunodeficiency virus infection Pharmacotherapy 24 2004 1732 1747 (Pubitemid 39578961)
39. S. Zucker, X. Qin, S. Rouster, F. Yu, R. Green, and P. Keshavan Mechanism of indinavir-induced hyperbilirrubinemia Proc Natl Acad Sci USA 98 2001 12671 12676
40. C.S. Huang, M.J. Huang, M.S. Lin, S.S. Yang, H.C. Teng, and K.S. Tang Genetic factors related to unconjugated hyperbilirrubinemia amongst adults Pharmacogenet Genom 15 2005 43 50
41. S. Rodríguez-Nóvoa, L. Martín-Carbonero, P. Barreiro, G. González-Pardo, I. Jiménez-Nácher, and J. González-Lahoz Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia AIDS 21 2007 41 46 (Pubitemid 44912535)
42. M.A. Boyd, P. Srasuebkul, K. Ruxrungtham, P.I. Mackenzie, V. Uchaipichat, and M. Stek Relationship between hyperbilirubinaemia and UDP- glucuronosyltransferase 1A1(UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir Pharmacogenet Genomics 16 2006 321 329
43. M. Rotger, P. Taffé, G. Bleiber, H.F. Günthard, H. Furrer, and P. Vernazza Gilbert Syndrome and the development of antiretroviral therapy-associated hyperbilirrubinemia J Infect Dis 192 2005 1381 1386 (Pubitemid 41401151)
44. S. Rodríguez Nóvoa, P. Barreiro, A. Rendón, A. Barrios, A. Corral, and I. Jiménez-Nacher Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C - >T polymorphism at the multidrug resistance gene 1 Clin Infect Dis 42 2006 291 295
45. W. Lewis, W.C. Copeland, and B.J. Day Mitochondrial DNA depletion, oxidative stress, and mutation: mechanisms of dysfunction from nucleoside reverse transcriptase inhibitors Lab Invest 81 2001 777 790 (Pubitemid 32553400)
46. S.C. Keswani, C.A. Pardo, C.L. Cherry, A. Hoke, and J.C. McArthur HIV-associated sensory neuropathies AIDS 16 2002 2105 2117 (Pubitemid 35387264)
47. M.J. Browne, K.H. Mayer, S.B. Chafee, M.N. Dudley, M.R. Posner, and S.M. Steinberg 2', 3'-didehydro-3'-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial J Infect Dis 167 1993 21 29 (Pubitemid 23002832)
48. T. Kelleher, A. Cross, and L. Dunkle Relation of peripheral neuropathy to HIV treatment in four randomized clinical trials including didanosine Clin Ther 21 1999 1182 1192 (Pubitemid 29380473)
49. T. Hulgan, D.W. Haas, J. Haines, M. Ritchie, G. Robbins, and R. Shafer Mitocondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS Clinical Trial Group study AIDS 19 2005 1341 1349 (Pubitemid 41800669)
50. J. Canter, D. Haas, A. Kallianpur, M. Ritchie, G. Robbins, and R. Shafer The mitochondrial phramacogenomics of haplogroup T: MTND2 (*) LHON4 917G and antiretroviral therapy-associated peripheral neuropathy Pharmacogenomics J 8 2008 71 77
51. A. Kallianpur, T. Hulgan, J. Canter, M. Ritchie, J. Haines, and G. Robbins Hemochromatosis (HFE) gene mutations and peripheral neuropathy during antiretroviral therapy AIDS 20 2006 1503 1513 (Pubitemid 44100211)
52. Lactic Acidosis International Study Group Risk factors for lactic acidosis and severe hyperlactataemia in HIV-1-infected adults exposed to antiretroviral therapy AIDS 21 2007 2455 2464
53. H. Yamanaka, H. Gatanaga, P. Kosalaraksa, S. Matsuoka-Aizawa, T. Takahashi, and S. Kimura Novel mutation of human DNA polymerase c associated with mitocondrial toxicity induced by anti-HIV treatment J Infect Dis 195 2007 1419 1425 (Pubitemid 46717459)
54. S. Coca, and M.A. Parazella Acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity Am J Med Sci 324 2002 342 344 (Pubitemid 36109329)
55. A. Karras, M. Lafaurie, A. Furco, A. Bourgarit, D. Droz, and D. Sereni Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus Clin Infect Dis 36 2003 1070 1073 (Pubitemid 36513295)
56. B.S. Rifkin, and M.A. Perazella Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure Am J Med 117 2004 282 284 (Pubitemid 39092726)
57. S. Padilla, F. Gutiérrez, M. Masiá, V. Cánovas, and C. Orozco Low frequency of renal function impairment during one-year of therapy with tenofovir-containing regimens in the real-world: a case-control study AIDS Patient Care STDS 19 2005 421 424 (Pubitemid 41105521)
58. M. Saumoy, F. Vidal, J. Peraire, S. Sauleda, A.M. Vea, and C. Viladés Proximal tubular kidney damage and tenofovir: a role for mitochondrial toxicity? AIDS 18 2004 1741 1742 (Pubitemid 39095796)
59. J.E. Gallant, M.A. Parish, J.C. Keruly, and R.D. Moore Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment Clin Infect Dis 40 2005 1194 1198
60. A. Mocroft, O. Kirk, J. Gatell, P. Reiss, P. Gargalianos, and K. Zilmer Chronic renal failure among HIV-1-infected patients AIDS 21 2007 1119 1127 (Pubitemid 46763282)
61. M.R. Nelson, C. Katlama, J.S. Montaner, D.A. Cooper, B. Gazzard, and B. Clotet The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years AIDS 21 2007 1273 1281 (Pubitemid 46883481)
62. A.E. Zimmermann, T. Pizzoferrato, J. Bedford, A. Morris, R. Hoffman, and G. Braden Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions Clin Infect Dis 42 2006 283 290 (Pubitemid 43054205)
63. M.D. Murphy, M. O'Hearn, and S. Chou Fatal lactic acidosis and acute renal failure after addition of tenofovir to an antiretroviral regimen containing didanosine Clin Infect Dis 36 2003 1082 1085 (Pubitemid 36513297)
64. H.M. Crane, B. Kestenbaum, R.D. Harrington, and M.M. Kitahata Amprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir AIDS 21 2007 1431 1439 (Pubitemid 46988003)
65. M. Masiá, F. Gutiérrez, S. Padilla, J.M. Ramos, and J. Pascual Didanosine-associated toxicity: a predictable complication of therapy with tenofovir and didanosine? J Acquir Immune Defic Syndr 35 2004 427 428 (Pubitemid 38332804)
66. M. Masiá, F. Gutiérrez, S. Padilla, J.M. Ramos, and J. Pascual Severe toxicity associated with the combination of tenofovir and didanosine: case report and review Int J STD AIDS 16 2005 646 648 (Pubitemid 41391547)
67. F. Vidal, J.C. Domingo, J. Guallar, M. Saumoy, B. Cordobilla, and R. Sánchez de la Rosa In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cells Antimicro Agents Chemother 50 2006 3824 3832 (Pubitemid 44684899)
68. N. Venhoff, B. Setzer, K. Melkaoui, and U.A. Walker Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with additional nucleoside reverse transcriptase inhibitors Antivir Ther 12 2007 1075 1085 (Pubitemid 350114988)
69. T. Cihlar, A.S. Ray, G. Laflamme, J.E. Vela, L. Tong, and M.D. Fuller Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors Antivir Ther 12 2007 267 272 (Pubitemid 46569912)
70. H. Motohashi, Y. Sakurai, H. Saito, S. Masuda, Y. Urakami, and M. Goto Gene expression levels and immunolocalization of organic ion transporters in the human kidney J Am Soc Nephrol 13 2002 866 874 (Pubitemid 34274082)
71. D.S. Miller Nucleoside phosphonate interactions with multiple organic anion transporters in renal proximal tubule J Pharmacol Exp Ther 299 2001 567 574
72. A. Ray, T. Cihlar, K. Robinson, L. Tong, J. Vela, and M. Fuller Mechanism of active renal tubular efflux of tenofovir Antimicrob Agents Chemother 50 2006 3297 3304 (Pubitemid 44527501)
73. H. Izzedine, J.S. Hulton, E. Villard, C. Goyenvalle, S. Dominguez, and J. Ghosn Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy J Infec Dis 194 2006 1481 1491 (Pubitemid 44851889)
74. A. Argiris, U. Mathur-Wagh, I. Wilets, and D. Mildvan Abnormalities of serum amylase and lipase in HIV-positive patients Am J Gastroenterol 94 1999 1248 1252 (Pubitemid 29214637)
75. M.S. Cappell, and M. Marks Acute pancreatitis in HIV-seronegative patients: a case control study of 44 patients Am J Med 98 1995 243 248
76. J.A. Cohn, K.J. Friedman, P.G. Noone, M.R. Knowles, L.M. Silverman, and P.S. Jowell Relation between mutations of the cystic fibrosis gene and idiopathic pancreatitis N Engl J Med 339 1998 653 658 (Pubitemid 28402089)
77. R.H. Pfützer, M.M. Barmada, A.P. Brunskill, R. Finch, P.S. Hart, and J. Neoptolemos SPINK1/PSTI polymorphisms act as disease modifiers in familial and idiopathic chronic pancreatitis Gastroenterology 119 2000 615 623 (Pubitemid 30681119)
78. C. Felley, M. Morris, A. Wonkam, B. Hirschel, M. Flepp, and K. Wolf The role of CFTR and SPINK-1 mutations in pancreatitis disorders in HIV-positive patients: a case-control study AIDS 18 2004 1521 1527 (Pubitemid 39037476)